NADK

Summary

NADK (NAD kinase, HGNC:29831) is a protein-coding gene on chromosome 1p36.33, encoding NAD kinase (O95544).

NADK catalyzes the transfer of a phosphate group from ATP to NAD to generate NADP, which in its reduced form acts as an electron donor for biosynthetic reactions (Lerner et al., 2001 [PubMed 11594753]).

Source: NCBI Gene 65220 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 97 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_023018

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29831
Approved symbol	NADK
Name	NAD kinase
Location	1p36.33
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13052, NADK1
Ensembl gene	ENSG00000008130
Ensembl biotype	protein_coding
OMIM	611616
Entrez	65220

Gene structure

Transcript identifiers

Ensembl transcripts: 42 — 30 protein_coding, 7 retained_intron, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000341426, ENST00000341991, ENST00000342348, ENST00000378625, ENST00000460602, ENST00000464373, ENST00000469045, ENST00000477235, ENST00000480499, ENST00000480542, ENST00000489538, ENST00000492768, ENST00000492845, ENST00000497186, ENST00000497615, ENST00000497747, ENST00000498806, ENST00000886130, ENST00000886131, ENST00000886132, ENST00000886133, ENST00000886134, ENST00000886135, ENST00000886136, ENST00000886137, ENST00000886138, ENST00000886139, ENST00000886140, ENST00000886141, ENST00000886142, ENST00000886143, ENST00000886144, ENST00000931657, ENST00000931658, ENST00000931659, ENST00000931660, ENST00000931661, ENST00000931662, ENST00000931663, ENST00000953973, ENST00000953974, ENST00000953975

RefSeq mRNA: 6 — MANE Select: NM_023018 NM_001198993, NM_001198994, NM_001198995, NM_001353641, NM_001353642, NM_023018

CCDS: CCDS30565, CCDS55561, CCDS55562

Canonical transcript exons

ENST00000341426 — 12 exons

Exon	Start	End
ENSE00001425950	1751232	1753060
ENSE00001430349	1778289	1778470
ENSE00001704992	1754051	1754208
ENSE00003487616	1761952	1762035
ENSE00003498213	1755374	1755476
ENSE00003514689	1754544	1754698
ENSE00003520839	1753567	1753649
ENSE00003537469	1756503	1756608
ENSE00003541571	1765228	1765446
ENSE00003606510	1757181	1757310
ENSE00003692625	1756258	1756343
ENSE00003693808	1754284	1754383

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 98.90.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 37.1476 / max 1141.6646, expressed in 1820 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
9824	19.7582	1778
9829	8.6737	392
9828	5.8582	287
9827	1.1216	180
9825	0.6607	299
9832	0.4900	195
9831	0.1386	70
9826	0.1145	59
9821	0.1088	76
9822	0.0875	55

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	98.90	gold quality
granulocyte	CL:0000094	98.65	gold quality
monocyte	CL:0000576	98.42	gold quality
mononuclear cell	CL:0000842	98.38	gold quality
leukocyte	CL:0000738	98.35	gold quality
spleen	UBERON:0002106	98.00	gold quality
right lobe of liver	UBERON:0001114	97.96	gold quality
right adrenal gland	UBERON:0001233	97.66	gold quality
right adrenal gland cortex	UBERON:0035827	97.66	gold quality
left adrenal gland cortex	UBERON:0035825	97.60	gold quality
left adrenal gland	UBERON:0001234	97.59	gold quality
adrenal cortex	UBERON:0001235	97.54	gold quality
adrenal gland	UBERON:0002369	97.04	gold quality
mucosa of transverse colon	UBERON:0004991	97.02	gold quality
mucosa of stomach	UBERON:0001199	96.71	gold quality
transverse colon	UBERON:0001157	96.50	gold quality
omental fat pad	UBERON:0010414	96.35	gold quality
peritoneum	UBERON:0002358	96.33	gold quality
body of stomach	UBERON:0001161	96.26	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.20	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.14	gold quality
pancreatic ductal cell	CL:0002079	96.00	gold quality
upper lobe of left lung	UBERON:0008952	95.96	gold quality
left coronary artery	UBERON:0001626	95.95	gold quality
left uterine tube	UBERON:0001303	95.91	gold quality
right coronary artery	UBERON:0001625	95.91	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.87	gold quality
lower esophagus	UBERON:0013473	95.85	gold quality
left ovary	UBERON:0002119	95.75	gold quality
coronary artery	UBERON:0001621	95.73	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.46
E-MTAB-9801	yes	9.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

64 targeting NADK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-4517	99.76	69.19	1867
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-3714	99.71	70.74	2671

Literature-anchored findings (GeneRIF, showing 9)

• NAD kinase levels control the NADPH concentration in human cells (PMID:17855339)
• Using purified human NAD kinase, we revealed a sigmoidal kinetic behavior toward ATP and the inhibitory effects of NADPH and NADH (PMID:21526340)
• Taken together, this indicates that Ser-188 (and perhaps the other residues) is an important phosphorylation site that can downregulate the NAD kinase activity of this critical enzyme. (PMID:26577408)
• Depletion of wild-type NADK in pancreatic ductal adenocarcinoma cells attenuates cancer cell growth. (PMID:26806015)
• Data indicate metabolic enzymes NAD kinase and ketohexokinase as candidate metabolic gene targets, and the chromatin remodeling protein INO80C as a tumor suppressor in KRAS(MUT) colorectal tumor xenograft. (PMID:28954733)
• These data indicate that Akt-mediated phosphorylation of NADK stimulates its activity to increase NADP(+) production through relief of an autoinhibitory function inherent to its amino terminus. (PMID:30846598)
• NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma. (PMID:34133937)
• G-protein-coupled estrogen receptor 1 promotes peritoneal metastasis of gastric cancer through nicotinamide adenine dinucleotide kinase 1-mediated redox modulation. (PMID:38315451)
• Knockdown of NADK promotes LUAD ferroptosis via NADPH/FSP1 axis. (PMID:38700533)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000006577
danio_rerio	nadka	ENSDARG00000098313
mus_musculus	Nadk	ENSMUSG00000029063
rattus_norvegicus	Nadk	ENSRNOG00000016936
drosophila_melanogaster	Nadk1a	FBGN0033853
drosophila_melanogaster	Nadk1b	FBGN0053156

Protein

Protein identifiers

NAD kinase — O95544 (reviewed: O95544)

Alternative names: Poly(P)/ATP NAD kinase

All UniProt accessions (6): O95544, A0A0A0MR98, J3KSP9, J3KTI3, J3QR86, J3QRC0

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Widely expressed but not detected in skeletal muscle.

Similarity. Belongs to the NAD kinase family.

Isoforms (3)

UniProt ID	Names	Canonical?
O95544-1	1	yes
O95544-2	2
O95544-3	3

RefSeq proteins (6): NP_001185922, NP_001185923, NP_001185924, NP_001340570, NP_001340571, NP_075394* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002504	NADK	Family
IPR016064	NAD/diacylglycerol_kinase_sf	Homologous_superfamily
IPR017437	ATP-NAD_kinase_PpnK-typ_C	Homologous_superfamily
IPR017438	ATP-NAD_kinase_N	Homologous_superfamily

Pfam: PF01513, PF20143

Enzyme classification (BRENDA):

• EC 2.7.1.23 — NAD+ kinase (BRENDA: 57 organisms, 133 substrates, 131 inhibitors, 140 Km, 41 kcat entries)

Substrate kinetics (BRENDA)

21 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.032–4.5	55
NAD+	0.022–6.5	55
POLYPHOSPHATE	2.2–2.7	4
GTP	0.2–2.86	3
NADH	0.042–2	3
NADP+	0.18–1.01	3
POLY(P)4	0.21–0.33	2
ADP	4.3	1
CTP	0.59	1
FRUCTOSE-1,6-BISPHOSPHATE	0.43	1
ITP	1.54	1
NADPH	0.3	1
POLYPHOSPHATE(20)	5.9	1
POLYPHOSPHATE(25)	17.2	1
POLYPHOSPHATE(45)	14.1	1

Catalyzed reactions (Rhea), 1 shown:

• NAD(+) + ATP = ADP + NADP(+) + H(+) (RHEA:18629)

UniProt features (54 total): strand 23, helix 10, turn 8, modified residue 5, sequence conflict 3, splice variant 3, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
9CRA	ELECTRON MICROSCOPY	2.34
8KGC	ELECTRON MICROSCOPY	2.54
3PFN	X-RAY DIFFRACTION	2.7
9CR4	ELECTRON MICROSCOPY	2.81
9CR3	ELECTRON MICROSCOPY	3.18

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95544-F1	80.56	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 46, 48, 50, 55, 64

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-196807	Nicotinate metabolism
R-HSA-1430728	Metabolism
R-HSA-196849	Metabolism of water-soluble vitamins and cofactors
R-HSA-196854	Metabolism of vitamins and cofactors

MSigDB gene sets: 224 (showing top): GOBP_NADPPLUS_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, CEBPB_01, GOBP_NADPLUS_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, MARTINEZ_RB1_TARGETS_DN, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_NUCLEOSIDE_TRIPHOSPHATE_METABOLIC_PROCESS, ACATTCC_MIR1_MIR206, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, HAN_SATB1_TARGETS_DN

GO Biological Process (5): NADP+ biosynthetic process (GO:0006741), phosphorylation (GO:0016310), NAD+ metabolic process (GO:0019674), positive regulation of insulin secretion involved in cellular response to glucose stimulus (GO:0035774), ATP metabolic process (GO:0046034)

GO Molecular Function (7): NAD+ kinase activity (GO:0003951), ATP binding (GO:0005524), metal ion binding (GO:0046872), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Metabolism of water-soluble vitamins and cofactors	1
Metabolism of vitamins and cofactors	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
purine nucleotide biosynthetic process	1
NADP+ metabolic process	1
nicotinamide nucleotide biosynthetic process	1
phosphate-containing compound metabolic process	1
purine nucleotide metabolic process	1
nicotinamide nucleotide metabolic process	1
positive regulation of insulin secretion	1
insulin secretion involved in cellular response to glucose stimulus	1
regulation of insulin secretion involved in cellular response to glucose stimulus	1
purine ribonucleotide metabolic process	1
purine ribonucleoside triphosphate metabolic process	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2289 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NADK	NADK2	Q4G0N4	792
NADK	NMNAT1	Q9HAN9	627
NADK	H6PD	O95479	617
NADK	NAPRT	Q6XQN6	617
NADK	NMNAT2	Q9BZQ4	604
NADK	A0A2R8YFG2	A0A2R8YFG2	604
NADK	G6PD	P11413	597
NADK	NADSYN1	Q6IA69	576
NADK	QPRT	Q15274	552
NADK	PGD	P52209	497
NADK	NAMPT	P43490	469
NADK	GPI	P06744	464
NADK	TALDO1	P37837	453
NADK	CALM1	P02593	447
NADK	RFK	Q969G6	446

IntAct

116 interactions, top by confidence:

A	B	Type	Score
YWHAG	NADK	psi-mi:“MI:0915”(physical association)	0.850
YWHAH	ABLIM1	psi-mi:“MI:0914”(association)	0.800
SDCBP	NADK	psi-mi:“MI:0915”(physical association)	0.780
NADK	SDCBP	psi-mi:“MI:0915”(physical association)	0.780
NADK	YWHAZ	psi-mi:“MI:0914”(association)	0.760
NADK	YWHAZ	psi-mi:“MI:0915”(physical association)	0.760
NADK	LNX1	psi-mi:“MI:0915”(physical association)	0.740
YWHAG	BLTP3B	psi-mi:“MI:2364”(proximity)	0.640
MCL1	PRKAB2	psi-mi:“MI:0914”(association)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAB	BLTP3B	psi-mi:“MI:2364”(proximity)	0.610
YWHAB	BLTP3B	psi-mi:“MI:0914”(association)	0.610
YWHAH	BLTP3B	psi-mi:“MI:2364”(proximity)	0.570
YEF1	NADK	psi-mi:“MI:0915”(physical association)	0.560
NADK	POS5	psi-mi:“MI:0915”(physical association)	0.560
POS5	NADK	psi-mi:“MI:0915”(physical association)	0.560
NADK	YEF1	psi-mi:“MI:0915”(physical association)	0.560
NADK	FAM124B	psi-mi:“MI:0915”(physical association)	0.560
NADK	CRY2	psi-mi:“MI:0915”(physical association)	0.560
NUDT18	NADK	psi-mi:“MI:0915”(physical association)	0.550
NADK	NUDT18	psi-mi:“MI:0915”(physical association)	0.550
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530

BioGRID (98): NADK (Two-hybrid), NADK (Affinity Capture-RNA), LNX1 (Two-hybrid), NADK (Two-hybrid), NUDT18 (Two-hybrid), NADK (Synthetic Lethality), NADK (Biochemical Activity), NADK (Affinity Capture-MS), NADK (Affinity Capture-MS), KIF13B (Affinity Capture-MS), NADK (Affinity Capture-MS), NADK (Affinity Capture-MS), GIGYF1 (Affinity Capture-MS), CGN (Affinity Capture-MS), LRFN1 (Affinity Capture-MS)

ESM2 similar proteins: A0JMG1, A2VE52, D3K5L7, E0CZ16, E1C6Q1, E2R222, F1LZ52, F1LZF0, F1MBP6, O13016, O35345, O43791, O60684, O95164, O95198, O95544, P35815, P36993, P54797, P58058, P63143, P63144, Q0IHH9, Q0V7M0, Q0VCW1, Q15645, Q28528, Q28F89, Q2M2N2, Q2TA46, Q3UA06, Q4PJK1, Q5BL35, Q5NVK7, Q5RBV0, Q5REP9, Q5U1X1, Q5XHZ9, Q6GR09, Q6IQ16

Diamond homologs: A0L8H9, A0LG64, A1KT64, A1VKP7, A1W4H1, A3CU51, A3DDM2, A6VXA6, A8ZWQ4, A9M3N9, B0K0V4, B0K9E7, B4RK90, B5EFY8, B7J4J4, B8FN99, B8I3A3, B9M5P5, B9ME57, C1A039, C1D6U5, C1DPY6, C4Z0G9, C5A3H8, C6E6I5, O13863, O95544, P21373, P32622, P58058, P65772, P65773, P73955, Q06892, Q0SS07, Q12DZ0, Q1ICQ6, Q1ISV1, Q1WSL8, Q2NEP6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 90 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	8	86.7×	5e-12
Activation of BAD and translocation to mitochondria	7	86.0×	9e-11
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	75.8×	2e-10
Activation of BH3-only proteins	7	56.1×	1e-09
RHO GTPases activate PKNs	8	40.9×	1e-09
Intrinsic Pathway for Apoptosis	7	33.1×	5e-08
FOXO-mediated transcription	5	27.1×	2e-05
Translocation of SLC2A4 (GLUT4) to the plasma membrane	8	19.9×	2e-07

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	6	26.8×	6e-05
Ras protein signal transduction	5	12.5×	6e-03
cellular response to insulin stimulus	5	10.4×	8e-03
intracellular protein localization	8	10.2×	3e-04
actin cytoskeleton organization	7	6.8×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

97 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	69
Likely benign	8
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

2521 predictions. Top by Δscore:

Variant	Effect	Δscore
1:1752926:T:TA	donor_gain	1.0000
1:1753013:C:T	acceptor_gain	1.0000
1:1753646:TGAT:T	acceptor_gain	1.0000
1:1753650:C:CC	acceptor_gain	1.0000
1:1754206:CTC:C	acceptor_gain	1.0000
1:1754282:A:AC	donor_gain	1.0000
1:1754283:C:CC	donor_gain	1.0000
1:1754379:AGGAC:A	acceptor_gain	1.0000
1:1754380:GGAC:G	acceptor_gain	1.0000
1:1754381:GAC:G	acceptor_gain	1.0000
1:1754382:AC:A	acceptor_gain	1.0000
1:1754382:ACC:A	acceptor_loss	1.0000
1:1754383:CC:C	acceptor_gain	1.0000
1:1754384:C:CA	acceptor_loss	1.0000
1:1754384:C:CC	acceptor_gain	1.0000
1:1754385:T:A	acceptor_loss	1.0000
1:1754542:A:AC	donor_gain	1.0000
1:1754543:C:CC	donor_gain	1.0000
1:1754695:TTCC:T	acceptor_gain	1.0000
1:1754696:TCC:T	acceptor_gain	1.0000
1:1754697:CC:C	acceptor_gain	1.0000
1:1754697:CCC:C	acceptor_gain	1.0000
1:1754698:CC:C	acceptor_gain	1.0000
1:1754698:CCTG:C	acceptor_loss	1.0000
1:1754707:C:CT	acceptor_gain	1.0000
1:1754707:C:T	acceptor_gain	1.0000
1:1754708:A:T	acceptor_gain	1.0000
1:1754710:C:CT	acceptor_gain	1.0000
1:1754717:C:CT	acceptor_gain	1.0000
1:1754718:A:T	acceptor_gain	1.0000

AlphaMissense

2944 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:1752964:C:A	W427C	1.000
1:1752964:C:G	W427C	1.000
1:1752966:A:G	W427R	1.000
1:1752966:A:T	W427R	1.000
1:1754180:G:C	S324R	1.000
1:1754180:G:T	S324R	1.000
1:1754182:T:G	S324R	1.000
1:1754184:C:T	G323D	1.000
1:1754208:C:T	G315E	1.000
1:1757251:A:G	L108P	1.000
1:1757276:A:G	W100R	1.000
1:1757276:A:T	W100R	1.000
1:1752961:G:C	N428K	0.999
1:1752961:G:T	N428K	0.999
1:1752965:C:G	W427S	0.999
1:1752996:A:G	W417R	0.999
1:1752996:A:T	W417R	0.999
1:1754055:A:G	L366P	0.999
1:1754073:A:T	V360D	0.999
1:1754098:A:G	S352P	0.999
1:1754101:G:C	H351D	0.999
1:1754105:G:C	C349W	0.999
1:1754107:A:G	C349R	0.999
1:1754127:G:T	A342D	0.999
1:1754128:C:G	A342P	0.999
1:1754160:G:T	A331D	0.999
1:1754173:A:G	Y327H	0.999
1:1754184:C:A	G323V	0.999
1:1754185:C:G	G323R	0.999
1:1754199:A:T	V318E	0.999

dbSNP variants (sampled 300 via entrez): RS1000157898 (1:1774163 GTA>G,GTATA), RS1000297994 (1:1758791 TG>T), RS1000335089 (1:1776271 C>A,T), RS1000388683 (1:1766959 C>G,T), RS1000417048 (1:1774293 C>T), RS1000455750 (1:1762957 G>A), RS1000511039 (1:1778381 G>T), RS1000515545 (1:1757007 C>A,T), RS1000542114 (1:1778445 G>C), RS1000568664 (1:1778921 G>A,C), RS1000679678 (1:1760812 C>T), RS1000828143 (1:1762688 T>C), RS1000846572 (1:1771166 A>G), RS1000917527 (1:1765257 C>T), RS1001046030 (1:1770996 C>T)

Disease associations

OMIM: gene MIM:611616 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST004278_58	Pulse pressure	2.000000e-06
GCST004278_60	Pulse pressure	2.000000e-10
GCST004279_36	Systolic blood pressure	1.000000e-12
GCST004904_247	Body mass index	2.000000e-09
GCST005951_34	Body mass index	3.000000e-08
GCST006585_2582	Blood protein levels	1.000000e-08
GCST007267_165	Systolic blood pressure	2.000000e-09
GCST007388_19	Insomnia symptoms (never/rarely vs. usually)	9.000000e-09
GCST009597_82	Multiple sclerosis	3.000000e-06
GCST010796_3550	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010796_3551	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_3552	Electrocardiogram morphology (amplitude at temporal datapoints)	6.000000e-09
GCST90002405_585	Reticulocyte count	5.000000e-10
GCST90002406_151	Reticulocyte fraction of red cells	1.000000e-09

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement
EFO:0006335	systolic blood pressure
EFO:0004340	body mass index
EFO:0007876	insomnia measurement
EFO:0004327	electrocardiography
EFO:0007986	reticulocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6177 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 22,804 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL297453	EPIGALOCATECHIN GALLATE	3	22,804

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

7 potent at pChembl≥5 of 18 total, top 7 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.02	IC50	960	nM	EPIGALOCATECHIN GALLATE
5.75	Kd	1780	nM	EPIGALOCATECHIN GALLATE
5.48	Ki	3280	nM	EPIGALOCATECHIN GALLATE
5.22	Ki	6000	nM	CHEMBL560315
5.22	Ki	6000	nM	CHEMBL562056
5.22	IC50	6000	nM	CHEMBL560315
5.22	IC50	6000	nM	CHEMBL562056

PubChem BioAssay actives

7 with measured affinity, of 72 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate	1865601: Inhibition of NADK delta 95 kinase domain (unknown origin) at 80 uM measured after 30 mins by HDX-MS analysis	ic50	0.9600	uM
(2S,3S,4R,5R)-2-[[[(2S,3S,4R,5R)-5-(6-amino-8-bromopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyldisulfanyl]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol	1865593: Inhibition of human NADK by HPLC analysis	ki	6.0000	uM
(2R,3R,4S,5S)-2-(6-amino-8-bromopurin-9-yl)-5-[[[(2S,3S,4R,5R)-5-(6-amino-8-bromopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyldisulfanyl]methyl]oxolane-3,4-diol	1865593: Inhibition of human NADK by HPLC analysis	ki	6.0000	uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, decreases expression	3
Arsenic	decreases expression, increases abundance, affects methylation, affects cotreatment	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases methylation	1
potassium perchlorate	decreases expression	1
beta-lapachone	decreases expression, increases expression	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
3-(1-deoxyribofuranosyl)benzamide	decreases activity, decreases abundance	1
benzamide adenine nucleotide	increases phosphorylation	1
motexafin gadolinium	increases expression, affects cotreatment	1
Bortezomib	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Air Pollutants, Occupational	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Cadmium	decreases expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Doxorubicin	decreases expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
NAD	increases phosphorylation	1
NADP	decreases abundance, decreases activity	1
Nickel	decreases expression	1
Ozone	affects expression, increases abundance	1
Quercetin	decreases phosphorylation	1
Smoke	increases expression	1

ChEMBL screening assays

16 unique, capped per target: 16 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1063153	Binding	Inhibition of human NAD kinase by modified HPLC based assay	Selective inhibition of nicotinamide adenine dinucleotide kinases by dinucleoside disulfide mimics of nicotinamide adenine dinucleotide analogues. — Bioorg Med Chem

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3BT	Abcam HEK293T NADK KO	Transformed cell line	Female
CVCL_XQ84	HAP1 NADK (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.